Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Preferred Research Partners Inc

Neither a doctor nor a teaching hospital

Research payments

$2,307,182

631 payments

Through program year 2025, Preferred Research Partners Inc is reported as receiving $2,307,182 in research payments, across 631 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $665,751 237
2024 Research $913,659 147
2023 Research $112,080 25
2022 Research $50,929 15
2021 Research $101,752 63
2020 Research $246,717 103
2019 Research $216,294 41

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $861,204 256 payments
  2. Janssen Research & Development, LLC $366,523 78 payments
  3. Novavax Inc $365,595 63 payments
  4. Vanda Pharmaceuticals Inc. $218,771 38 payments
  5. Allergan Inc. $203,972 82 payments
  6. Braintree Laboratories, Inc. $186,762 42 payments
  7. Supernus Pharmaceuticals, Inc. $53,461 10 payments
  8. Moderna TX, Inc. $33,278 23 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $11,701 1 payment
  10. Phathom Pharmaceuticals, Inc. $5,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years $221,513 19 payments
  2. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $218,137 40 payments
  3. Evaluating the Safety and Efficacy of Tradipitant VS. Placebo in Idiopathic and Diabetic Gastroparesis $203,826 32 payments
  4. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $188,562 28 payments
  5. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $126,726 17 payments
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $120,262 34 payments
  7. A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age $104,705 36 payments
  8. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $78,255 21 payments
  9. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine $73,868 22 payments
  10. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $64,740 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record